cochlear implantation
Procedurepatients receive a cochlear implantation within clinical routine
NCT Number: NCT04610112
This is a prospective study designed to evaluate the safety and performance of the HiRes Ultra Cl HiFocus MS Electrode and HiRes Ultra 3D Cl HiFocus MS Electrode (Ultra X) under normal conditions of use as it is approved for this device.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Heilig Geist Hospital Bensheim, Bensheim, Hesse, Germany
This study is set up to document any adverse events and comparing pre- to post-implant benefit to subjects. Any adverse events associated with the device will be documented via Advanced Bionics complaint handling system for the lifetime of the device. A within-subjects repeated-measures design will be employed. Speech perception will be evaluated preoperatively with conventional amplification to determine candidacy and to establish baseline performance. Efficacy parameters are speech perception data which will be collected according to clinical routine with a 6 month follow up period. Subjects will be implanted unilaterally with the Ultra X according to standard clinical care.
The primary efficacy objective is to demonstrate that mean monosyllabic word recognition score with the Ultra X used in combination with a sound processor programmed with the latest fitting software six months after activation is at least 20% better than the mean word score at baseline with conventional amplification in the same ear.
The primary efficacy endpoint is reached six months after device activation.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
patients receive a cochlear implantation within clinical routine
Time frame: 6 months
score in % correct (scale from 0 to 100% of correct answers)
Time frame: 6 months
50 % SRT in the Oldenburger Sentence Test (OlSa) in noise. Results expressed in dB Signal-Noise-Ratio (SNR)
Advanced Bionics AG
Industry
Clinical Investigation of the Safety and Performance of HiRes Ultra Cl HiFocus MS Electrode (Cl-1600-04) and HiRes Ultra 3D Cl HiFocus MS Electrode (Cl-1601-04) (Ultra X Implants) in Adults With Severe-to-profound Hearing Loss
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04929470
Cochlear Hearing Loss, Ear Diseases
Düsseldorf, Germany
View Trial DetailsNCT06301568
Cochlear Hearing Loss, Ear Diseases
Hanover, Germany
View Trial DetailsNCT07091071
Cochlear Hearing Loss, Cochlear Synaptopathy
Antwerp, Belgium
View Trial DetailsNCT04048239
Cochlear Hearing Loss, Ear Diseases
Amiens, France
View Trial Details